The United States liquid
biopsy market is anticipated to grow at an impressive CAGR for the forecast
period, 2023-2027. Rising preference for non-invasive treatment procedures and
increasing incidence and prevalence of cancer are the primary factors driving
the demand for the United States liquid biopsy market in the forecast period.
Increasing Prevalence of Cancer Drives
the Market Growth
Rise in tobacco
consumption, lifestyle changes and environmental factors, and contamination
with infectious agents such as Hepatitis B and C are some of the factors
causing cancer in a large number of individuals. According to WHO, cancer is
considered one of the leading causes of death of patients at the global level.
Liquid biopsy is in high demand among healthcare professionals for cancer
treatment as it is highly effective compared to traditional cancer diagnostics
techniques. Liquid biopsy offers several advantages such as increased patient
comfort, acquired drug resistance, lower cost, therapy monitoring, early prognosis,
and detection of tumor heterogeneity over traditional treatment methods.
Rise In Awareness About
Non-Invasive Treatment Method Boosts Market Growth
Liquid biopsy has revolutionized cancer
treatment as it is a simple and non-invasive treatment and provides a better
alternative to invasive surgical biopsies. It helps the healthcare
professionals to discover a plethora of information about the tumor through a
simple sample. The method is quick and provides real-time information about the
current condition.
At present, liquid biopsy treatment includes circulating
tumor DNA (ctDNA), circulating tumor cells (CTC), and exosomes for which the
samples can be taken through blood, saliva, urine of the patient. The
non-invasive nature of liquid biopsy is the main reason for its high demand
among healthcare professionals. It requires only 5 milliliters of blood, making
the process tolerable, convenient, and quicker for the patients than the
invasive methods. One of the significant advantages of liquid biopsy is it can
detect treatment resistance or disease progression beforehand than it appears
on imaging scans or shows clinical symptoms.
High Demand for Companion Diagnostics
Supports The Market Growth
Companion diagnostics include tests or
assays, which play a crucial role in providing cancer patients with information
to determine the effective and safe use of the biological product or
corresponding drug. Healthcare providers can compare the benefits of the drug,
which should ideally outweigh the potential side-effect or risks for the
patient.
Companion diagnostics can optimize and improve the drug development
process by helping in the identification of safer drugs having higher
therapeutic efficacy. They minimize the chances of error and make the drugs
affordable and the drug production process more cost-effective. The demand for
quality treatment and effective drugs boosts the adoption of companion
diagnostics by drug manufacturers and research and diagnostic centers. High
penetration of companion diagnostics due to growing awareness about the
advantages of the process is expected to support the growth of the United
States liquid biopsy market throughout the forecast period.
Click here to download the sample
Market Segmentation
The United States liquid biopsy market
is divided into product & services, circulating biomarker,
technology, application, end user, regional distribution, and company. Based on the product
& services, the market is divided into assay kits, instruments, services. Based on the circulating biomarker,
the market is divided into circulating tumor cells, circulating
tumor DNA (ctDNA), cell-free DNA (cfDNA), and others.
Based on the technology,
the market is divided into multi-gene parallel analysis using NGS and
single-gene analysis using PCR microarrays. Based on application, the market is divided into cancer and
non-cancer. Based on the end
user, the market is divided into hospitals & clinics, reference
laboratories, others. To
analyze the market based on the region, the United States liquid biopsy market
is studied in major regions namely Southern region, Western region, Mid-Western
region, and North-Eastern region.
Market Players
Thermo Fischer Scientific, Inc.,
Guardant Health, Inc., Biocept, Inc., Roche Diagnostics Corporation, Myriad
Genetics, Inc., Exact Sciences Corporation, Illumina, Inc., Bio-Rad
Laboratories, Inc., Biocept, Inc., NeoGenomics, Inc., Vortex Biosciences, Inc.,
Exosome Diagnostics, Inc., Agena Bioscience, Inc., MedGenome Inc., Personal
Genome Diagnostics, Inc., are among the major market players operating in the United
States liquid biopsy market.
|
Attribute
|
Details
|
|
Base Year
|
2021
|
|
Historic Data
|
2017 –
2020
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023
– 2027
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
|
|
Report coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments covered
|
·
Product & Services
·
Circulating Biomarker
·
Technology
·
Application
·
End User
|
|
Regional scope
|
South,
West, Mid-West, North-East
|
|
Key companies profiled
|
Thermo Fischer Scientific, Inc., Guardant Health, Inc., Biocept,
Inc., Roche Diagnostics Corporation, Myriad Genetics, Inc., Exact Sciences
Corporation, Illumina, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., NeoGenomics,
Inc., Vortex Biosciences, Inc., Exosome Diagnostics, Inc., Agena Bioscience,
Inc., MedGenome Inc., Personal Genome Diagnostics, Inc.
|
|
Customization scope
|
10%
free report customization with purchase. Addition or alteration to regional
& segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and
Excel through Email (We can also provide the editable version of the report
in PPT/Word format on special request)
|
Report Scope:
In this report, United States liquid
biopsy market has been segmented into following categories, in addition to the
industry trends which have also been detailed below:
- United States Liquid Biopsy Market, By Product
& Services:
- Assay Kits
- Instruments
- Services
- United States Liquid Biopsy Market, By Circulating
Biomarker:
- Circulating Tumor Cells
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
- Others
- United States Liquid Biopsy Market, By Technology:
- Multi-gene Parallel Analysis using
NGS
- Single-gene Analysis using PCR
Microarrays
- United States Liquid Biopsy Market, By Application:
- United States Liquid Biopsy Market, By End User:
- Hospitals & Clinics
- Reference Laboratories
- Others
- United States Liquid
Biopsy Market, By Region:
- South
- West
- Mid-West
- North-East
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in United States liquid biopsy market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
United States liquid biopsy market is
an upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]